On night one, fixed CPAP preserved sleep continuity better than the auto version
Both machine types cut breathing interruptions equally well in a 108-patient study. But auto-adjusting PAP's constantly shifting pressure came with more time awake and less total sleep on night one.
Positive airway pressure therapy comes in two main forms: fixed CPAP, which delivers a constant pressure set in advance, and auto-adjusting PAP (APAP), which continuously varies pressure in response to detected breathing events through the night. Both are standard treatments for obstructive sleep apnea, but a study published this month in Sleep and Breathing finds they don't behave identically on the first night a patient uses one [s1].
The design
This was a retrospective study of 108 adults with obstructive sleep apnea who underwent diagnostic polysomnography followed by an in-laboratory polysomnography night with PAP therapy — 54 on APAP and 54 on fixed CPAP [s1]. Researchers recorded sleep continuity, sleep stages, and respiratory indices, and used device data to quantify pressure changes, pressure range, and the 95th-percentile pressure delivered, correlating these with changes in total sleep time, wake after sleep onset (time spent awake after initially falling asleep), and sleep efficiency [s1]. Baseline characteristics and apnea-hypopnea index (AHI, a standard severity measure) were similar between the two groups going in [s1].
What it found
On the respiratory side, the two devices performed comparably: both APAP and fixed CPAP markedly reduced AHI, with no significant difference between groups in how well they controlled breathing events [s1].
On sleep continuity, though, they diverged. APAP was associated with decreased total sleep time, increased wake after sleep onset, and reduced sleep efficiency compared with fixed CPAP, where these measures remained stable [s1]. The study also found that APAP produced more frequent and wider pressure changes and higher 95th-percentile pressures than fixed CPAP — and that this pressure variability showed modest correlations with the poorer sleep continuity measures [s1].
What might explain the difference
APAP's core design feature — pressure that rises and falls in response to detected breathing events, rather than staying constant — is also its proposed liability here: those pressure shifts appear to be at least partly responsible for the increased wakefulness and reduced sleep efficiency observed, based on the correlation the researchers found between pressure variability and continuity measures [s1]. That's a plausible, if not definitively proven, mechanism — a pressure that changes throughout the night, particularly with wide swings, could itself be a subtle arousal stimulus even as it's successfully preventing the breathing events it's designed to catch.
What this does and doesn't mean for patients starting PAP therapy
This study is specific to the very first night of PAP use in a laboratory setting — a context that matters, because first-night effects with any new device or environment (including polysomnography itself, sometimes called the "first-night effect") are a well-recognized phenomenon in sleep medicine, separate from how a device performs after a patient has adapted to it over weeks. The study doesn't address whether the sleep-continuity difference persists, narrows, or disappears after patients acclimate to either device type over subsequent nights or weeks — a meaningfully different and more clinically relevant question than what happens on night one alone.
The study's authors suggest that limiting the initial pressure range and avoiding large pressure fluctuations during PAP initiation may reduce this early sleep disruption [s1] — a practical, device-configuration-level recommendation rather than an argument against APAP generally, since APAP's adaptive pressure is also its main advantage for many patients over the course of ongoing treatment.
What this doesn't establish
This is a retrospective, single-night study of 108 patients, not a randomized trial, and treatment assignment (APAP versus CPAP) reflects whatever a given center or clinician chose for their patient, which may correlate with other unmeasured differences between the two groups. The study measures continuity, not downstream outcomes like daytime sleepiness, quality of life, or long-term treatment adherence, which are arguably what matters most to patients starting therapy.
What to watch
Whether the sleep-continuity difference persists beyond the first night, and whether adjusting APAP's pressure range at initiation — as the authors suggest — measurably improves early sleep quality without compromising the device's adaptive advantage. This article is not medical advice, and choice of PAP device should be made with a treating clinician.
Sources
Sources
More on
Patients with insomnia and apnea saw a bigger blood-pressure drop from CPAP
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
CPAP still outperforms mouth-guard alternatives, but the size of the gap is unclear
Pooling eight trials, oral appliances left nearly 12 more breathing events per hour than CPAP. But the trials disagreed with each other so much that the researchers say that number itself should be read with caution.
In heart patients with apnea but no sleepiness, CPAP still improved cardiac features
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.
A beta blocker blunted sleep apnea's heart-rate spikes, but cost some sleep quality
Researchers deliberately withdrew CPAP for three nights to simulate untreated sleep apnea, then tested propranolol against placebo. It slowed the heart-rate surges tied to apnea events, at the price of lighter sleep.